<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are clonal disorders of the hematopoietic system with resultant cytopenias and shortened survival </plain></SENT>
<SENT sid="1" pm="."><plain>Better recognition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and an aging population, some of whom have been treated with chemotherapy and radiation therapy for other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, is largely responsible for the growing incidence of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, which is divided into lower- and higher-risk subtypes </plain></SENT>
<SENT sid="2" pm="."><plain>Erythropoiesis-stimulating agents are the first-line treatment options for patients with lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and symptomatic <z:hpo ids='HP_0001903'>anemia</z:hpo> or for those requiring transfusion support </plain></SENT>
<SENT sid="3" pm="."><plain>Lenalidomide has been successfully used for patients with the del(5q) chromosomal abnormality who are also transfusion dependent </plain></SENT>
<SENT sid="4" pm="."><plain>Hypomethylating agents, such as <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi>, are indicated for patients with higher-risk disease, with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> demonstrating a survival advantage </plain></SENT>
<SENT sid="5" pm="."><plain>Hematopoietic stem cell transplantation (HSCT) is a curative therapeutic approach available to less than 5% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Combination therapies and newer single agents targeting the important cellular pathways are being explored for treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with promising results </plain></SENT>
</text></document>